Moderna reported its first positive Phase 3 trial for an mRNA-based personalized cancer vaccine (NeoMune) in melanoma, marking a major milestone for neoantigen immunotherapy. The therapy is designed to train patients' immune systems to target tumor-specific mutations identified from their own cancer tissue.
Background
NeoMune is Moderna's investigational personalized mRNA neoantigen therapy for melanoma, following promising Phase 2 data. This Phase 3 success could establish a new standard of care for high-risk melanoma patients.
- Source
- Hacker News (RSS)
- Published
- Aug 19, 2026 at 09:33 PM
- Score
- 9.0 / 10